Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Characterization and interactions between piperine and ezetimibe in their Anti-hyperlipidemic efficacy using Biopharmaceutics and Pharmacokinetics.
BMC Pharmacol Toxicol
January 2025
Department of Pharmaceutics and Pharmaceutical Technology, Kampala International University, Western Campus, P.O. Box 71, Ishaka - Bushenyi, Uganda.
Background: Piperine, a secondary metabolite, affects the antihyperlipidemic effect of Ezetimibe (EZ). Hyperlipidemia is one of the independent risk factors for cardiovascular disorders such as atherosclerosis. Antihyperlipidemic drugs are essential for reducing cardiovascular events and patient mortality.
View Article and Find Full Text PDFRice Bran Consumption Improves Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
Nutrients
December 2024
Department of Food Science and Biotechnology, Seoul National University of Science and Technology, 232 Gongneung-ro, Nowon-gu, Seoul 01811, Republic of Korea.
Background: Dyslipidemia, a leading risk factor for cardiovascular diseases (CVDs), significantly contributes to global morbidity and mortality. Rice bran, rich in bioactive compounds such as γ-oryzanol and tocotrienols, has demonstrated promising lipid-modulating effects.
Objective: This meta-analysis aimed to evaluate the effects of rice bran on lipid profiles, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C), and identify factors influencing its efficacy across different populations and intervention conditions.
[Distribution and epidemic trends of chronic multimorbidity among adult residents in 10 provinces (autonomous regions)of China in 2009-2023].
Wei Sheng Yan Jiu
November 2024
NHC Key Laboratory of Public Nutrition and Health, National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China.
Objective: To describe the prevalence and epidemic trends of several chronic multimorbidy among adult residents in 10 provinces(autonomous regions)of China over the past 14 years, and to analyze their multimorbidity patterns.
Methods: According to the fasting blood physiological and biochemical tests, physical measurements and questionnaires of 17 000 adult residents aged 18 years and above who were surveyed in 4 rounds of follow-up surveys in 2009, 2015, 2018 and 2023, the relevant indicators and disease history information of obesity, hypertension, diabetes mellitus, dyslipidemia, hyperuricemia, and various chronic diseases were obtained. Descriptive analysis was carried out to identify and compare several common combinations of multimorbidity in the population with 2 or more chronic disease conditions and the changing trends of 4 rounds of surveys.
[Status and epidemic trends of major chronic metabolic diseases among adult residents in 10 provinces (autonomous regions) of China in 2009-2023].
Wei Sheng Yan Jiu
November 2024
National Institute for Nutrition and Health, Chinese Center for Disease Control and Prevention, Beijing 100050, China NHC Key Laboratory of Public Nutrition and Health, Beijing 100050, China.
Objective: To analyze the status and epidemic trends of major chronic metabolic diseases among adults.
Methods: Using the "China Health and Nutrition Survey"(2009-2018)/"China Development and Nutrition Health Impact Cohort Survey"(2022-2023), adults aged 18 years old and above from 10 provincial regions were selected as the study subjects. Those with missing demographic information and disease diagnosis were removed, and a total of 34 982 people were finally included from 2009, 2015, 2018 and 2023 waves.
[Clinical comprehensive evaluation of Jiangzhi Tongluo Soft Capsules for treating hyperlipidemia (syndrome of blood stasis and Qi stagnation)].
Zhongguo Zhong Yao Za Zhi
October 2024
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences Beijing 100700, China.
This study provides a systematic review of existing evidence concerning the efficacy of Jiangzhi Tongluo Soft Capsules(JTSC) in treating hyperlipidemia(syndrome of blood stasis and Qi stagnation), following the Guidelines for clinical evidence and value assessment of drugs. The qualitative and quantitative methods were integrated, including questionnaire surveys, evidence-based medicine, and pharmacoeconomic evaluation. Multi-criteria decision analysis(MCDA) model was used for comprehensive assessment of the clinical evidence and value of JTSC for hyperlipidemia in "6+1" dimensions: safety, effectiveness, cost-effectiveness, innovation, suitability, accessibility, and traditional Chinese medicine(TCM) characteristics.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!